None
DE
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Given Consensus Rating of “Moderate Buy” by Brokerages
['Shane Hupp']
Ticker Report
LADENBURG THALM/SH SH started coverage on shares of Alterity Therapeutics in a research report on Tuesday, June 16th.
Get Alterity Therapeutics alerts:Read Our Latest Stock Report on Alterity TherapeuticsAlterity Therapeutics Price PerformanceInstitutional Inflows and OutflowsATHE opened at $4.58 on Tuesday.
A hedge fund recently bought a new position in Alterity Therapeutics stock.
Alterity Therapeutics Company Profile(Get Free Report)Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders.
Featured ArticlesReceive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.